Trace level quantitation of multiple compounds - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trace level quantitation of multiple compounds

Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology. As the flagship model of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) product line, the LCMS-8050 features high sensitivity, high data quality and the world’s fastest data acquisition rates.

Delivering attogram-level (10-18 grams) sensitivity and possessing unsurpassed ruggedness, the LCMS-8050 achieves its improved sensitivity through two important technologies:

  • Newly designed Heated ESI source improves desolvation and enhances ionization efficiency with the addition of a heated gas used in combination with the nebulizer gas
  • UFsweeper®III collision cell enhances CID efficiency by optimizing the collision cell pressure.

The world’s fastest data acquisition rates
The newly engineered high voltage power supply enables a maximum scan rate of 30,000 u/sec and a 5 msec polarity switching time, making the LCMS-8050 combined with Nexera UHPLC the ideal platform for laboratory productivity. It is now possible to include 1,000 events with up to 32 channels per event for a maximum of 32,000 MRMs per analysis.

User-friendly Operation and Easy Maintenance

  • Plug-in for the new ion source enables easy changing from ESI to APCI or to dual ionization mode (DUIS)
  • The LabSolutions LCMS Version 5.60 software provides seamless integration of HPLC and MS control. An automated MRM optimization routine allows unattended optimization of multiple compounds.

For more information please visit www.shimadzu.eu

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
FindPharma Custom Search

Click here